



**Pfizer Announces a [Research Grant RFP](#)**  
***2021 Global ANGPTL3 ASPIRE\****  
***Cardiovascular Competitive Grant Program -***  
***using Expert Review Panel***

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.

**\*ASPIRE: Advancing Science and Patient care through Innovative Research and Education**

## Competitive Grant Program Eligibility

<b>Geographic Scope</b>	<ul style="list-style-type: none"> <li>• Global</li> </ul>
<b>Applicant Eligibility Criteria</b>	<p>To be eligible:</p> <ul style="list-style-type: none"> <li>• Only organizations are eligible to receive grants, not individuals or medical practice groups.</li> <li>• The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.</li> <li>• Applicant must be affiliated with a host institution.</li> <li>• Both early career and experienced investigators are encouraged to apply and consideration will be given to all proposals meeting the selection criteria.</li> </ul>

## Requirements

<b>Date RFP Issued</b>	<ul style="list-style-type: none"> <li>• February 1, 2021</li> </ul>
<b>Clinical Area</b>	<ul style="list-style-type: none"> <li>• Dyslipidemia and atherosclerotic cardiovascular disease (ASCVD)</li> </ul>
<b>Area of Interest Focus</b>	<ul style="list-style-type: none"> <li>• The intent of this Request for Proposal (RFP) is to support basic science, pre-clinical research and clinical research through a competitive grants program that advances medical knowledge of the role of ANGPTL3 in health and disease. Innovative research may be in any of the following areas:             <ul style="list-style-type: none"> <li>○ Role of ANGPTL3 in lipid/lipoprotein metabolism and relevance to ASCVD and pancreatitis</li> <li>○ Elucidation of ANGPTL3 biology in health and disease. Examples may include but are not limited to:                 <ul style="list-style-type: none"> <li>▪ Cellular and receptor interactions</li> <li>▪ Inflammation/Immuno-inflammatory response</li> <li>▪ Monocyte-macrophage biology</li> <li>▪ Smooth muscle cell biology</li> <li>▪ Lymphocyte biology</li> </ul> </li> </ul> </li> </ul>

	<ul style="list-style-type: none"> <li>▪ Insulin resistance/pancreatic beta cells</li> <li>▪ Adipose tissue</li> <li>▪ Hepatic lipid metabolism/fatty liver/ectopic fat</li> <li>▪ Pancreatitis</li> <li>▪ Kidney/liver axis</li> <li>▪ Blood-brain barrier/cognitive function</li> <li>▪ Plaque biology</li> <li>○ ANGPTL3 genetics and gene regulation</li> <li>○ ANGPTL3 in vascular biology/hematopoiesis</li> <li>○ Elucidation of ANGPTL3 biology in human disease. Examples may include but are limited to:             <ul style="list-style-type: none"> <li>▪ Atherosclerosis</li> <li>▪ Infectious disease</li> <li>▪ Renal disease</li> <li>▪ Autoimmune and rheumatological diseases</li> <li>▪ Type 2 diabetes</li> <li>▪ Metabolic syndrome</li> </ul> </li> <li>• The following types of research projects are considered in scope and will be eligible for this program:             <ul style="list-style-type: none"> <li>○ Basic science, pre-clinical research and clinical research that aligns with the in-scope research topics (i.e., animal models, in vivo/in vitro studies)</li> <li>○ Animal experimentation related to human biology</li> <li>○ Translational studies</li> </ul> </li> <li>• Out of scope research includes:             <ul style="list-style-type: none"> <li>○ Any study involving the use of an ANGPTL3 therapy</li> <li>○ Studies involving investigational products</li> <li>○ Highly invasive studies and studies that may have an ethical concern</li> <li>○ Mere replication of existing studies (i.e., lack of innovation)</li> </ul> </li> </ul>
<p><b>Expected Approximate Monetary Range of Grant Applications</b></p>	<ul style="list-style-type: none"> <li>• Individual projects requesting up to USD \$250,000 will be considered. Pfizer anticipates a total fund of USD \$750,000. Research is expected to be completed and submitted for presentation/publication within 3 years of study start. Smaller, high-quality, innovative grant requests with anticipated results within 12-18 months will be enthusiastically considered.</li> </ul>

	<ul style="list-style-type: none"> <li>The amount of the grant Pfizer will be prepared to fund for any project will depend upon the expert review panel's evaluation of the proposal and costs involved and will be stated clearly in the approval notification.</li> </ul>
<p><b>Key Dates</b></p>	<ul style="list-style-type: none"> <li>RFP release date: February 1, 2021</li> <li><b>LOI due date: March 12, 2021</b> [Please note the deadline is 23:59 Eastern Time (New York, GMT -5).]</li> <li>Review of LOIs by ERP: May 10, 2021</li> <li>Anticipated LOI Notification Date: May 17, 2021</li> <li>Full Proposal Deadline: *July 2, 2021 *Only accepted LOIs will be invited to submit full proposals [Please note the deadline is 23:59 Eastern Time (New York, GMT -5).]</li> <li>Review of Full Proposals by ERP: August 20, 2021</li> <li>Anticipated Full Proposal Notification Date: September 9, 2021</li> </ul>
<p><b>How to Apply</b></p>	<ul style="list-style-type: none"> <li>Please go to <a href="http://www.cybergrants.com/pfizer/loi">www.cybergrants.com/pfizer/loi</a> and sign in. First-time users should click "Create your password".</li> </ul> <p>Requirements for submission:</p> <ul style="list-style-type: none"> <li>Select the following Competitive Grant Program Name: <b>2021 IM G: ANGPTL3 ASPIRE</b></li> <li>Complete all required sections of the online application. See <b>Appendix A</b> for additional details.</li> <li>If you encounter any technical difficulties with the website, please click the "Technical Questions" link at the bottom of the page.</li> </ul>
<p><b>Questions:</b></p>	<ul style="list-style-type: none"> <li>If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jessica Romano (Jessica.Romano@pfizer.com), with the subject line "ASPIRE ANGPTL3 Cardiovascular Competitive Research Grants Program."</li> <li>Please click <a href="#">here</a> to view Frequently Asked Questions regarding the Competitive Grant Program.</li> </ul>
<p><b>Grant Agreements:</b></p>	<ul style="list-style-type: none"> <li>If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click <a href="#">here</a> to view the core terms of the agreement.</li> <li>Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to</li> </ul>

	abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety.
<b>Review and Approval Process</b>	<ul style="list-style-type: none"><li>• Grant requests received in response to a specific RFP are reviewed by an expert review panel (ERP) to make final grant decisions.</li><li>• The panels are comprised of professionals from the medical community with advanced degrees and expertise in particular clinical areas, or specific needs of a geographic region/learner group, or expertise in research, continuing professional development or quality improvement.</li></ul>
<b>Mechanism by which Applicants will be Notified:</b>	<ul style="list-style-type: none"><li>• All applicants will be notified via email by the dates noted above.</li><li>• Applicants may be asked for additional clarification during the review period.</li></ul>

## Appendix A

### Letter of Intent Requirements

**The Letter of Intent (LOI) will be accepted via the online application. When answering the LOI questions in the application please keep the following in mind:**

<b>Goals and Objectives</b>	<ul style="list-style-type: none"> <li>Provide the main goal of the study and the study population (if applicable). Provide a detailed definition that is directly linked to the primary objective.</li> </ul>
<b>Assessment of Need for the Project</b>	<ul style="list-style-type: none"> <li>This should reflect your study rationale. Provide a brief description of the medical/scientific question and the rationale of how this trial or study addresses the question.</li> </ul>
<b>Target Audience</b>	<ul style="list-style-type: none"> <li>Describe the primary audience(s) targeted for this project. For Investigator Sponsored Clinical Trials, please specify the age, gender and other demographic information for trial population.</li> <li>Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.</li> </ul>
<b>Project Design and Methods</b>	<ul style="list-style-type: none"> <li>Describe concisely the research design and methods for achieving the stated goals. For a clinical interventional study, include inclusion/exclusion criteria, treatment plan and statistical plan.</li> </ul>
<b>Innovation</b>	<ul style="list-style-type: none"> <li>Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.</li> </ul>
<b>Evaluation and Outcomes</b>	<ul style="list-style-type: none"> <li>Specify type and frequency of safety, efficacy, and/or outcome measures. Also indicate the method(s) used to assess measures.</li> <li>Provide a publication plan describing intended submission of abstracts to (a) congress(es) or intended submission of (a) publication(s) to peer-reviewed journals. All publications must follow ICH guidelines.</li> </ul>
<b>Anticipated Project Timeline</b>	<ul style="list-style-type: none"> <li>Provide an anticipated timeline for your project including project start/end dates.</li> </ul>
<b>Additional Information</b>	<ul style="list-style-type: none"> <li>If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.</li> <li>Early-career applicants: Letter(s) of support from mentor(s) and collaborators describing how the award will advance the applicant's career.</li> </ul>

## Organization Detail

- This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and “other”]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project.